Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3)

被引：0
|
作者：
Piha-Paul, Sarina A.
Call, Justin A.
Spira, Alexander I.
Bartolome, Jorge
de Miguel, Maria J.
Du, Yangchun
DiLea, Clifford
Panchabhai, Sonali
Lakhani, Nehal J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[2] START Mt Reg, West Valley City, UT USA
[3] NEXT Oncol Virginia, Fairfax, VA USA
[4] UTEC Hosp Clin San Carlos, Madrid, Spain
[5] START Madrid CIOCC, Madrid, Spain
[6] Mural Oncol, Waltham, MA USA
[7] START Midwest, Grand Rapids, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2587
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
    Hamid, Omid
    Liu, Stephen V.
    Boccia, Ralph V.
    Call, Justin A.
    Wise-Draper, Trisha Michel
    Alistar, Angela Tatiana
    Powderly, John D.
    Carthon, Bradley Curtis
    Vaishampayan, Ulka N.
    Olszanski, Anthony J.
    Wrangle, John M.
    Shields, Anthony Frank
    Piha-Paul, Sarina Anne Anne
    Desai, Monali
    Du, Yangchun
    Sun, Lei
    Wang, Yan
    Losey, Heather
    Hopkinson, Craig
    Ernstoff, Marc S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors
    Piha-Paul, Sarina Anne
    Elliott, Corrine F.
    Du, Yangchun
    Graham, Julie R.
    Desai, Monali
    Wang, Yan
    Lakhani, Nehal J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Debio 0123+carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
    Gelderblom, H.
    Gadea, O. Saavedra Santa
    Jalving, M.
    Desar, I.
    Gietema, J. A.
    Oberoi, A.
    Van Herpen, C.
    Kroep, J. R.
    Franzen, R. Frederiksen
    Bellon, A.
    Micallef, S.
    Tat, T.
    Dozio, V.
    Luong, N.
    Imedio, E. Rodrigo
    ANNALS OF ONCOLOGY, 2024, 35 : S502 - S503
  • [4] Determination of a recommended Phase 2 dose (RP2D) for SRF388, a first-in-class IL-27-blocking antibody, in patients with advanced solid tumors
    Hill, Jonathan A.
    White, Kerry F.
    Rausch, Matthew
    Chung, Jou-Ku
    Patnaik, Amita
    Naing, Aung
    Morgensztern, Daniel
    Mantia, Charlene M.
    Tannir, Nizar M.
    Smith, Lon S.
    Bowers, Beth
    Alika, Alex
    Harshman, Lauren C.
    Lee, Benjamin H.
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
    Vaishampayan, Ulka N.
    Muzaffar, Jameel
    Winer, Ira
    Rosen, Seth D.
    Hoimes, Christoper J.
    Chauhan, Aman
    Spreafico, Anna
    Lewis, Karl D.
    Bruno, Debora S.
    Dumas, Olivier
    Mcdermott, David F.
    Strauss, James F.
    Chu, Quincy S.
    Gilbert, Lucy
    Chaudhry, Arvind
    Calvo, Emiliano
    Dalal, Rita
    Boni, Valentina
    Ernstoff, Marc S.
    Velcheti, Vamsidhar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (11)
  • [6] Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial
    Yamazaki, K.
    Tsushima, T.
    Shitara, K.
    Sarholz, B.
    Fujita, M.
    Doi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S75 - S76
  • [7] Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A)
    Lassaletta, Alvaro
    Moreno, Lucas
    Ogawa, Chitose
    Ruggiero, Antonio
    Hoffman, Lindsey M.
    Pitou, Celine
    Zhou, Yanhong
    Hardebeck, Molly C.
    Knoderer, Holly
    Juan-Ribelles, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), and to determine the recommended phase 2 dose (RP2D) of subcutaneous (SC) cetrelimab (CET) in patients (pts) with advanced solid malignancies.
    Rutkowski, Piotr
    Kowalski, Dariusz
    Moreno, Victor
    Calvo, Aitana
    Thistlethwaite, Fiona
    Plummer, Elizabeth Ruth
    Han, Kevin Tianxiang
    Loffredo, John
    Carcione, Jenna
    Jonathan, Daniel
    Philip, Vinod
    Baig, Mahadi
    Hellemans, Peter
    Bulat, Iurie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D)
    El-Khoueiry, A.
    Gitlitz, B.
    Cole, S.
    Tsao-Wei, D.
    Goldkorn, A.
    Quinn, D.
    Lenz, H. J.
    Nieva, J.
    Dorff, T.
    Oswald, M.
    Berg, J.
    Menendez, X.
    Karakozian, K.
    Krasnoperov, V.
    Liu, R.
    Thomas, J.
    Groshen, S.
    Gill, P.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [10] Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
    Li, B. T.
    Lee, K-W.
    Pegram, M.
    Sharma, M. R.
    Lee, J.
    Spira, A. I.
    Kang, Y-K.
    Moore, K. N.
    Rasco, D.
    Hanna, G. J.
    Weinberg, B. A.
    Yu, T.
    Alonso, M.
    Ptacek, J.
    Yin, M.
    Tapia, C.
    Xu, L.
    Perez, E. A.
    Dumbrava, E. E.
    ANNALS OF ONCOLOGY, 2023, 34 : S462 - S463
12345